Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma

Published:2019-11-18 Issue:3 Volume:61 Page:691-698
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Hoylman Emily¹,Brown Anna¹,Perissinotti Anthony J.¹,Marini Bernard L.¹,Pianko Matthew²^ORCID,Ye Jing Christine²,Campagnaro Erica²,Nachar Victoria R.¹

Affiliation:

1. Department of Pharmacy Services and Clinical Sciences, Michigan Medicine, University of Michigan College of Pharmacy, Ann Arbor, MI, USA;

2. Department of Internal Medicine, Division of Hematology and Oncology, Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1688324

Reference21 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies

2. Impact of Novel Treatments on Multiple Myeloma Survival

3. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

4. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

5. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma;Blood Cancer Journal;2024-09-05

2. Daratumumab‑resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report;Oncology Letters;2024-04-03

3. Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma;Frontiers in Cell and Developmental Biology;2024-02-12

4. Monoclonal Antibodies in the Treatment of Multiple Myeloma;Hematology/Oncology Clinics of North America;2023-12

5. NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma;HemaSphere;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3